Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Femasys Inc. SEC filings document the company’s women’s health medical-device business, Nasdaq-listed common stock, operating results, and product-related corporate updates. Recent 8-K filings furnish quarterly and annual financial results and disclose material events tied to executive appointments, employment agreements, financing instruments, and listing compliance matters.
Proxy materials cover annual and special stockholder meetings, board elections and governance matters, reverse stock split authorization, and share-issuance approvals linked to capital-structure provisions. Other filings describe senior secured convertible notes, warrant amendments, Nasdaq minimum bid price compliance, and the company’s emerging growth company reporting status.
FEMASYS INC (FEMY), a Delaware biotechnology corporation, filed a Form D for a Regulation D exempt offering under Rule 506(b). The notice relates to a new offering of equity and options, warrants or other rights to acquire securities, with the date of first sale reported as August 10, 2026.
The company reports a total amount sold of $30,000,000 USD and a total remaining to be sold of $0 USD, indicating the offering is fully subscribed at this level. No finders' fees are reported. FEMASYS classifies itself within the health care – biotechnology industry and declines to disclose its revenue range.
Femasys Inc. (FEMY) received a significant investment from funds managed by Nantahala Capital Management. On August 7, 2026, Nantahala-affiliated investors agreed to pay the company $11,999,705.22 in cash to purchase 802,145 shares of common stock, pre-funded warrants for up to 2,947,855 shares at $0.001 per share, common warrants for up to 3,750,000 shares at $2.95 per share, and milestone warrants for up to 3,750,000 shares at $2.95 per share.
As of August 10, 2026, the reporting group beneficially owned 803,038 shares, or 9.99% of Femasys’ 8,038,419 outstanding shares, reflecting warrant exercisability subject to a 9.99% Beneficial Ownership Limitation. The milestone warrants become exercisable only if Femasys reaches $1,500,000 in U.S. revenue in any fiscal quarter and the stock trades at least 130% of the exercise price for 20 of 30 consecutive trading days.
A side letter grants Nantahala governance rights for up to ten years after the purchase, including the right to designate one or two board members depending on ownership thresholds (at least 15% and 20% of outstanding shares, calculated without the ownership cap) and consent rights over specified actions such as incurring more than $2,500,000 of indebtedness. A registration rights agreement requires Femasys to file and seek effectiveness of a shelf resale registration statement covering shares issuable upon exercise of the warrants.
Femasys Inc. reported continued operating losses while significantly strengthening its balance sheet through post‑quarter financing. For the six months ended June 30, 2026, sales were $756,716, roughly flat versus 2025, but second‑quarter sales fell 18.9% year over year to $331,827, mainly from lower international FemVue sales. Operating expenses for the quarter rose 28.1% to $5.3 million, driven by higher research and development, sales and marketing, and general and administrative spending as the company advances FemBloc and commercializes FemaSeed and related products.
Loss from operations was $9.3 million for the first half, similar to 2025, but the net loss narrowed sharply to $3.6 million from $10.5 million, primarily due to non‑cash gains of $5.96 million from remeasuring and then reclassifying the conversion option and warrant liabilities on the 2025 convertible notes to equity. Cash and cash equivalents declined to $1.44 million from $9.27 million at year‑end, reflecting $8.1 million of operating cash outflows and modest ATM and ESPP equity issuance.
After quarter‑end, Femasys completed a private placement of common stock and pre‑funded warrants expected to generate about $30 million of gross proceeds, with additional potential proceeds from three‑year warrants. Management states that, including this financing, liquidity is sufficient for at least 12 months. In June 2026 the company also effected a 1‑for‑20 reverse stock split to comply with Nasdaq listing requirements.
Femasys Inc. reported results for the quarter and six months ended June 30, 2026 while highlighting a recently completed $30 million private placement that, together with restored Nasdaq compliance, is described as strengthening the foundation for its U.S. commercial strategy for the FemaSeed fertility portfolio and advancement of the FemBloc clinical and regulatory program toward potential U.S. approval.
For the quarter, sales were $331,827 with cost of sales of $142,436 and total operating expenses of $5,255,265, leading to a loss from operations of $5,065,874. Including fair value gains on warrant and conversion option liabilities, net loss for the quarter was $4,469,095. For the six months ended June 30, 2026, net loss narrowed to $3,622,995 compared with $10,482,761 in the prior-year period, despite similar operating losses.
On the balance sheet at June 30, 2026, cash and cash equivalents were $1,443,502, total assets were $12,289,582, total liabilities were $8,258,635 and stockholders’ equity was $4,030,947. The company continues to advance commercialization of FemaSeed and the FemBloc FINALE pivotal trial, supported by prior regulatory approvals for FemBloc in Europe, the UK and New Zealand.
Femasys Inc. reports that investment entities affiliated with Rosalind Advisors Inc. have filed as significant holders of its common shares. Rosalind Advisors Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon each report potential beneficial ownership of up to 9.99% of the common stock, based on 8,037,526 shares outstanding as of August 10, 2026. Their position comprises 723,377 common shares plus 3,964,123 additional shares issuable upon exercise of warrants, subject to blocker provisions that cap effective ownership below the reported maximum.
FEMASYS INC director Kenneth D. Eichenbaum received a grant of 880 stock options on June 24, 2026. The options have an exercise price of $3.67 per share, relate to 880 shares of common stock, and vest one year from the grant date assuming continued service. The options expire on June 24, 2036, and following this grant he holds 880 options directly.
FEMASYS INC director Edward R. Uzialko received a grant of 880 stock options on 2026-06-24. Each option has an exercise price of $3.67 and is exercisable for one share of common stock, covering a total of 8,800 underlying shares. The options were granted at no purchase cost and will vest one year from the grant date, assuming continued service, and are scheduled to expire on 2036-06-24. Following this grant, Uzialko holds 880 derivative securities of this type directly.
Femasys Inc. director Alistair Milnes received a new stock option award. On 2026-06-24, he was granted options to acquire 880 shares of Femasys common stock at an exercise price of $3.67 per share, expiring on 2036-06-24. The underlying shares vest one year from the grant date, assuming continued service, and this grant brings his directly held stock options from this award to 880 options.
FEMASYS INC reported that director Charles Larsen received a grant of stock options. The award covers 880 Stock Options (Right to Buy) with an exercise price of $3.67 per share, expiring on June 24, 2036. These options relate to 880 shares of Common Stock and were acquired at a price of $0.00 per option as compensation. According to the company’s disclosure, the shares underlying the option vest one year from the date of grant, assuming continued service. Following this grant, Larsen holds 880 derivative securities of this type directly.
Femasys Inc. executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, acquired equity-linked interests on August 7, 2026. He purchased 3,125 shares of common stock at $3.20 per share for an aggregate $10,000, and received two warrants for 3,125 shares each with a $2.95 exercise price, one immediately exercisable (subject to Nasdaq-related limitations) and one tied to future revenue and stock-price milestones.